Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (1): 132-137    DOI: 10.31083/j.ceog.2021.01.5495
Original Research Previous articles | Next articles
The impact of major uterine wall resection and reconstruction of the uterus (MURU) on uterine hemodynamics and ovarian function in patients with adenomyosis: a clinical study
Yan-Bing Xiao1, Meng Mou1, Heng-Fang Gu1, Hui-Xing Li1, Meng-Yuan You1, Zhi-Gang Liang1, Lei Han1, *()
1Maternal and Child Health Hospital Affiliated to Zunyi Medical University, 563000 Guizhou Province, P. R. China
Download:  PDF(18385KB)  ( 35 ) Full text   ( 13 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Previous studies had shown that major uterine wall resection and reconstruction of the uterus (MURU) was safe and effective in the treatment of adenomyosis. However, MURU results in loss of a significant amount of myometrial and some endometrial tissues, which may have an impact on uterine hemodynamics and ovarian function. Therefore, it is necessary to study the changes of uterine hemodynamics and ovarian function in patients after MURU, in order to provide an evidence-base for its clinical application. Objective: To explore the effects of major uterine wall resection and reconstruction of the uterus (MURU) on uterine hemodynamics and ovarian function in patients with adenomyosis. Study design: The maximum thickness of unilateral uterine muscle wall or the maximum diameters of adenomyosis focus were measured by ultrasonography. Patients with adenomyosis were divided into three groups: mild, moderate or severe. Fifty cases of adenomyosis without fertility requirement were treated with MURU (observation group), and levonorgestrel-releasing system (LNG-IUS) was placed in uterine cavity during the operation. Fifty patients with intramural myoma of the uterus were selected for hysteromyomectomy (control group). The changes of arterial pulsation index (PI) and resistance index (RI) of uterine artery, as well as antral follicle count (AFC) and serum antimullerian hormone (AMH) were observed before operation and 1 month, 3 months, 6 months, 12 months and 18 months post-operation. Results: No complications were observed in both groups, no significant difference in uterine hemodynamics and ovarian function were found between the two groups (P > 0.05). During intragroup comparison, there were no significant changes in PI and RI before and after operation in the two groups, and no significant changes in AFC and AMH were detected in both groups before and after operation (P > 0.05). Conclusions: MURU did not significantly affect the uterine hemodynamics and ovarian function in patients with adenomyosis, but the long-term effects need to be further investigated.
Key words:  MURU      Adenomyosis      Uterine hemodynamics      Ovarian function     
Submitted:  17 January 2020      Revised:  10 May 2020      Accepted:  25 May 2020      Published:  15 February 2021     
Fund: 
81460233/National Natural Science Foundation Project of China (NSFC)
81660293/National Natural Science Foundation Project of China (NSFC)
*Corresponding Author(s):  Lei Han     E-mail:  hanleimm@126.com

Cite this article: 

Yan-Bing Xiao, Meng Mou, Heng-Fang Gu, Hui-Xing Li, Meng-Yuan You, Zhi-Gang Liang, Lei Han. The impact of major uterine wall resection and reconstruction of the uterus (MURU) on uterine hemodynamics and ovarian function in patients with adenomyosis: a clinical study. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 132-137.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.01.5495     OR     https://ceog.imrpress.com/EN/Y2021/V48/I1/132

[1] Ja Young Kim, Yun Gyu Song, Chang-Woon Kim, Moon Ok Lee. Uterine artery embolization using gelatin sponge particles for symptomatic focal and diffuse adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 59-65.
[2] Xiao-Cen Niu, Li-Hua Zhu, Zhi-Da Qian, Li-Li Huang. Disseminated intravascular coagulation developed after suction curettage in an adenomyosis patient: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 189-193.
[3] Jong-Kil Joo, Chae-Hak Lim, Min Jung Park, Hyeon Jeong Kim, Chang-Woon Kim, Chul-Hee Yoon, Jeong-Eun Yoo, Bo Sun Joo. Effect of seven oriental herbs mixture (Jogyeongbohyeoldan) on the restoration of ovarian aging in aged mice[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 37-46.
[4] S.Y. Song, G.W. Lee, J.B. Yang, D.E. Kim, D.B. Park, H.J. Yoo. Septic shock caused by abscess formation inside cystic adenomyosis after responsive treatment of pelvic inflammatory disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 983-987.
[5] H. Takagi, S. Yamada, J. Sakamoto, S. Fujita, T. Sasagawa. Hemostatic effects of kyukikyogaito in dienogest treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 560-564.
[6] H.S. Song, Y.A. Kim. Placenta percreta at 33 weeks of gestation after laparoscopic radiofrequency ablation for adenomyosis and Conservative Surgical Treatment: A case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 600-603.
[7] A. Pontis, L. Nappi, F. Sorrentino, S. Angioni. Differential diagnosis of adenomyosis: the role of hysteroscopy and laparoscopy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 511-515.
[8] H. Kwon, J.E. Shin, H. Kim. A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 637-640.
[9] H. Takagi, J. Sakamoto, T. Sasagawa. Long-term treatment of endometriosis with dienogest for up to five years[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 398-402.
[10] Jae-Seong Lee, Tae-Eung Kim, Jang Heub Kim, Byung Joon Park. Unintended pregnancies with term delivery following ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation of uterine fibroid and adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 842-844.
[11] Sha A Dai Ti, Wu Fu Er, Zhao Lei, A Yi Nu Er, Mai Su Ti, Gu Li Na, A Ba Bai Ke Li. Clinical evaluation of three methods in the treatment of adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 508-512.
[12] Ju-Qi Ma, Chun-Fen Guo, Ayshamgul Hasim. Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 387-390.
[13] H. Takagi, T. Sasagawa, Y. Osaka. Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 312-315.
[14] Lu-lu Fu, Li-ping Zheng, Hai-long Bao, Ya-fei Meng, Chun-hui Gu, Lian-wen Zheng. A giant cystic adenomyoma mimicking the degeneration of uterine myoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 961-963.
[15] T. Matsushima, S. Akira, H. Asakura, T. Takeshita. Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(1): 143-145.
No Suggested Reading articles found!